Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.